A fragment of human growth hormone that targets fat metabolism without the growth-promoting effects of full HGH.
AOD-9604 is a modified fragment of human growth hormone (hGH) corresponding to amino acids 176–191 of the hGH sequence. Originally developed by Monash University in Australia as part of an anti-obesity drug program, it was designed to isolate the lipolytic (fat-burning) properties of HGH without triggering the growth-promoting, insulin-desensitizing, or carcinogenic risks associated with full HGH administration. The peptide completed Phase IIb clinical trials for obesity and received GRAS (Generally Recognized as Safe) status from the FDA for use as a food additive, making it one of the few research peptides with a formal safety assessment. Beyond fat loss, preclinical research has suggested potential applications in cartilage repair and osteoarthritis, adding to its research interest.
* Benefits based on preclinical/animal research unless otherwise noted.
“A fragment of human growth hormone that targets fat metabolism without the growth-promoting effects of full HGH.”
AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by activating beta-3 adrenergic receptors in adipose tissue, directly mimicking the fat-metabolizing action of the C-terminal region of HGH. Critically, because it lacks the N-terminal portion of HGH responsible for IGF-1 stimulation, it does not elevate blood glucose, raise IGF-1 levels, or promote cell proliferation. The peptide also appears to activate AMP-activated protein kinase (AMPK), a key cellular energy sensor that promotes fat oxidation. In cartilage studies, it has been shown to stimulate proteoglycan synthesis and inhibit matrix metalloproteinases (MMPs), suggesting a role in joint tissue preservation independent of its metabolic effects.
Protocol Notes: Administer in the morning in a fasted state for maximum fat-burning effect. Exercise within 30–60 minutes of injection to enhance lipolysis.
Add 2 mL bacteriostatic water to 5 mg vial → 2500 mcg/mL For 500 mcg dose: draw 0.2 mL (20 units on U-100 syringe)
When sourcing AOD-9604 for research purposes, the following quality benchmarks should be verified before use.
Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.
Lyophilized: room temperature up to 3 months, refrigerated up to 2 years. Reconstituted: refrigerate and use within 30 days.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Limited Evidence — Primarily animal studies with limited human data. Mechanism is plausible but clinical efficacy is unconfirmed.
Peptides commonly used alongside AOD-9604 for synergistic effects.
GLP-1 Receptor Agonist
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management with robust cardiovascular benefits.
Learn More: SemaglutideGrowth Hormone Releasing Peptide (GHRP)
The most selective GHRP available, stimulating GH release with minimal cortisol or prolactin elevation.
Learn More: Ipamorelin